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Background/Aims: In patients with corticosteroid-refractory 
ulcerative colitis (UC), cyclosporine or infliximab may be 
added to the treatment regimen to induce remission. Here, 
we aimed to compare the efficacy of cyclosporine and inflix-
imab. Methods: Between January 1995 and May 2012, the 
medical records of 43 patients with corticosteroid-refractory 
UC who received either infliximab or cyclosporine as a rescue 
therapy at a tertiary care hospital in Korea were reviewed. 
Results: Among the 43 patients, 10 underwent rescue 
therapy with cyclosporine and the remaining 33 patients 
received infliximab. A follow-up of 12 months was completed 
for all patients. The colectomy rate at 12 months was 30% 
and 3% in the cyclosporine and the infliximab groups, re-
spectively (p=0.034). However, the Cox proportional hazard 
model indicated that the treatment of rescue therapy was 
not an independent associate factor for preventing colectomy 
(p=0.164). In the subgroup analysis, infliximab with azathio-
prine was superior to cyclosporine for preventing colectomy 
(hazard ratio of infliximab with azathioprine compared with 
cyclosporine only, 0.073; 95% confidence interval, 0.008 to 
0.629). Conclusions: No difference between infliximab and 
cyclosporine with respect to preventing colectomy was noted. 
However, infliximab with azathioprine may be more effective 
than cyclosporine alone for preventing colectomy. (Gut Liver 
2015;9:601-606)
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INTRODUCTION
Acute severe ulcerative colitis (UC) is a potentially lethal clini-
cal condition that requires intensive medical treatment and po-
tential colectomy in cases of treatment failure.1,2 A recent study 
showed that acute colitis can occur in up to 25% of patients 
with UC.3,4 Use of intravenous corticosteroids has been shown to 
modify the natural history of severe acute relapses, but approxi-
mately 30% to 40% of patients fail to respond to this intensive 
treatment.5,6 Both infliximab and cyclosporine have been shown 
to be effective in inducing remission or at least delaying sur-
gery in patients with severe UC that is refractory to intravenous 
high-dose corticosteroids.1,7-9
Cyclosporine is an immunosuppressant that inhibits T-cell 
mediated production of interleukin 2 (IL-2).10 Acute remis-
sion rates achieved with the use of cyclosporine have ranged 
between 63% and 82% in previous trials.10-13 Although these 
studies showed some benefits of cyclosporine treatment, there is 
a significant risk of toxicity that can result in hypertension, sei-
zures, renal impairment, and hypomagnesaemia, which require 
intensive monitoring.14 In the last 10 years, infliximab, which 
is a monoclonal antibody that binds free and membrane-bound 
tumor necrosis factor α, has been shown to be an effective 
treatment for severe UC. At a dosage of 5 mg/kg, infliximab can 
help to reduce the risk of colectomy.15
A recent retrospective review investigating outcomes of pa-
tients treated with either infliximab or cyclosporine as a rescue 
therapy for UC requiring hospitalization concluded that there is 
no difference between the two with respect to induction of clini-
cal remission or avoiding urgent colectomy at 3 months.8,11,16,17 
Moreover, in a European study17 treatment failure was noted in 
35 of 58 patients (60%) given cyclosporine compared with 31 
of 57 (54%) given infliximab (p=0.52). There was no difference 
See editorial on page 567.
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between the two groups in terms of treatment failure.17 Most 
of these data, however, have been reported in Western popula-
tions which have different genetic and ethnic backgrounds than 
Asian populations. To date, there has been little data on use of 
these treatments in Asian countries. According to the first data 
reported in a Korean population that investigated the efficacy of 
infliximab in patients with UC, the rates of clinical response and 
remission were 87% and 45% after 8 weeks and long-term were 
71% and 62%, respectively.18 They concluded that infliximab 
is effective and safe in the treatment of active UC in Korean 
patients. The study, however, evaluated the efficacy of inflix-
imab only without group comparison. We, therefore, aimed to 
compare the efficacy of infliximab with that of cyclosporine in 
severe steroid-refractory UC patients in Korean population. 
MATERIALS AND METHODS
1. Patients
We reviewed records from a series of patients with severe 
corticosteroid-refractory UC admitted to Severance Hospital 
between January 1995 and May 2012 and compared outcomes 
after treatment with cyclosporine or infliximab. The diagnosis of 
UC was made according to previously established international 
criteria based on clinical, endoscopic, histopathologic, and ra-
diographic findings.19 Intravenous corticosteroid-resistant UC is 
defined as a lack of response to an adequate dosage of cortico-
steroids within 5 to 7 days.20 Patients were eligible for inclusion 
in this study if they had been hospitalized between January 
1995 and May 2012 for treatment of acute UC that was refrac-
tory to intravenous hydrocortisone, and they were subsequently 
treated with either intravenous cyclosporine or infliximab. 
Between 1995 and 2005, all patients seen at our clinic with 
severe UC refractory to intravenous corticosteroids were treated 
with cyclosporine at the dosage of 2 mg/kg daily, with adjust-
ments in dosage based on blood levels of cyclosporine (thera-
peutic range, 160 to 360 μg/L). Intravenous cyclosporine was 
continued until a response was achieved, and then the patient 
was switched to azathioprine. From 2006 to the present, patients 
with this condition were treated with infliximab at the dosage 
of 5 mg/kg after screening for infection or malignancy. Patients 
who responded to infliximab without clinical signs of intoler-
ance completed the induction phase with infusions at weeks 2 
and 6 followed by scheduled infusions (5 mg/kg every 8 weeks). 
In some patients treated with infliximab or cyclosporine, 
azathioprine was started soon after the last infusion. If previous 
intolerance or failure of immunomodulators had been reported, 
maintenance treatment with azathioprine was not performed. 
In all patients in whom cyclosporine or infliximab failed, 
a total colectomy was performed. Cyclosporine or infliximab 
failure was determined by a physician after a global assessment, 
and a clinical decision was made regarding whether continued 
medical treatment or an emergency colectomy was appropriate 
within 5 to 7 days. 
2. Data collection
All medical records were retrospectively reviewed. Our team 
has utilized a specialized medical record form at our inflamma-
tory bowel diseases clinic for the past 20 years. Patients were 
interviewed by clinical research coordinators and invited to an-
swer a study questionnaire, which addressed data related to UC 
forms that scored clinical activity. A physician’s global assess-
ment was performed for each patient at every outpatient clinic 
visit or hospitalization. The accumulated data were converted 
into indices of clinical disease activity for this study. The fol-
lowing information was collected: type of intervention, age, sex, 
extent of disease, duration of disease prior to admission, length 
of intravenous corticosteroid treatment prior to intervention, 
and medications at time of admission. The extent of disease was 
measured by colonoscopy or sigmoidoscopy based on patients’ 
conditions. Laboratory measurements were also recorded includ-
ing erythrocyte sedimentation rate, hemoglobin, and albumin 
at the start of and throughout the course of treatment. The date 
of colectomy was also recorded for each patient. The C-reactive 
protein (CRP) level was checked at the start of treatments.
3. End-points
The primary end-point was a colectomy-free survival. Sec-
ondary end-points were colectomy rates at 3 and 12 months, 
remission inducing and maintenance rates at 3 and 12 months, 
length of hospital stay after initiation of either treatment, steroid 
requirement at 12 months, and adverse events. 
4. Statistical analysis
Continuous variables including age, duration of disease 
prior to intervention, and CRP level were summarized as 
means±standard deviations or medians with ranges according 
to their distribution. Categorical variables including drugs for 
rescue therapy, disease extension, and number of patients on 
azathioprine therapy at the time of treatment were summarized 
as frequencies and percentages. Statistical analysis included 
Student t-tests, Mann-Whitney U tests, chi-square tests, and 
Fisher exact tests. Kaplan-Meier plots and log-rank tests were 
performed for survival analysis of the two treatment groups. A 
Cox proportional hazards model was proposed in order to adjust 
for confounding variables. We considered the following possible 
confounders: age, disease duration, length of treatment with 
intravenous corticosteroids, use of azathioprine, length of hos-
pitalization, CRP values, disease extension. Variables with sig-
nificance of 0.2 or less on univariate analysis were included as 
covariates in a Cox proportional hazards model. If the discrep-
ancy of results between univariate and multivariate analyses 
was identified, subgroup analysis was performed for evaluating 
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the reason of discrepancy. A p-value <0.05 was regarded as sig-
nificant for between group comparisons. All statistical analyses 
were performed using SPSS version 18.0 for Windows (SPSS 
Inc., Chicago, IL, USA).
RESULTS
1. Clinical characteristics of study subjects
A total of 43 patients were included in the final analysis: 10 
in the cyclosporine group and 33 in the infliximab group. Pa-
tient characteristics are shown in Table 1. The median follow-
up period was 119.4 months (range, 22.5 to 207.8 months) in 
the cyclosporine group and 50.6 months (range, 11.2 to 195.7 
months) in the infliximab group. Four patients (40%) in the 
cyclosporine group and 28 patients (84.8%) in the infliximab 
group were taking azathioprine on admission. 
2. Outcomes
A 12-month follow-up was completed for all patients. Three 
months after the acute episode requiring either cyclosporine 
or infliximab treatment, the colectomy rate was 10% (1 of 10) 
in the cyclosporine group and 0% (0 of 33) in the infliximab 
group (p=0.233). At 12 months, the colectomy rate increased 
to 30% in the cyclosporine group versus 3% in the infliximab 
group (p=0.034) (Table 2). In terms of remission inducing and 
maintenance rates, clinical remission was achieved numerically 
more frequently in infliximab group, but that was not statisti-
cally significant between the two groups (30.0% vs 45.5%, 
p=0.485). Moreover, remission maintenance rates at 12 months 
were also not significantly different between the two groups 
(20.0% vs 48.5%, p=0.153). At the end of the follow-up, the 
colectomy had been performed in six of 10 patients and one 
of 33 patients in the cyclosporine and the infliximab groups, 
respectively (cyclosporine vs infliximab, 60% vs 3%; p<0.001). 
In six cases of patients who underwent colectomy after the 
treatment with cyclosporine, the median time to colectomy was 
11.3 months with range of 1.7 to 21.3 months. The one patient 
who underwent colectomy after being treated with infliximab, 
the colectomy was done at 7.6 months after the treatment. The 
cumulative colectomy rates are shown in the Kaplan-Meier plot 
in Fig. 1. Colectomy-free survival in the infliximab group was 
superior to that in the cyclosporine group (p<0.001). In contrast 
to the result of univariate analysis, Cox proportional hazard 
Fig. 1. Kaplan-Meier plots for colectomy-free survival according to 
the drug for rescue therapy.
0
1.0
0.8
0.6
0.4
0.2P
ro
b
a
b
ili
ty
o
f
s
u
rv
iv
a
l
Days to colectomy
0
50 100 150 200
p<0.001
Cyclosporin
Infliximab
Table 1. Baseline Characteristics of Patients with Severe Ulcerative Colitis
Characteristic Cyclosporine (n=10) Infliximab (n=33) p-value
Age, yr
Male sex
Duration of disease prior to intervention, mo
Disease extension
   Extensive colitis
   Nonextensive colitis
      Left-sided colitis
      Rectosigmoid colitis
      Proctitis
C-reactive protein (mg/L) at the time of treatment
Patients on azathioprine therapy at the time of treatment 
56 (22–72)
3 (30.0)
121.4 (0–216)
8 (80.0)
1 (10.0)
1 (10.0)
0 
10.9 (1.9–48.0)
4 (40.0)
44 (15–71)
25 (75.8)
76.3 (0–192)
12 (36.4)
3 (9.1)
16 (48.5)
2 (6.1)
30.0 (28–489)
28 (84.8)
0.678
0.008
0.506
0.028*
0.057
0.004
Data are presented as median (range) or number (%).
*p-value between the extensive colitis and nonextensive colitis groups.
Table 2. Colectomy Rates at 3 Months, 12 Months, and at the End of 
the Follow-Up Period
Colectomy rate Cyclosporine Infliximab p-value
3 Months (%)
12 Months (%)
3 Years (%)
1 (10.0)
3 (30.0)
6 (60.0)
0 
1 (3.0)
1 (3.0)
0.233
0.034
<0.001
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model showed that the drug for rescue therapy was not related 
to the colectomy-free survival (hazard ratio [HR] of infliximab 
compared to cyclosporine, 0.166; 95% confidence interval [CI], 
0.013 to 2.088) (Table 3). In addition, we proposed another Cox 
proportional hazard model for colectomy in patients treated 
with either cyclosporine only or infliximab with azathioprine, 
because most patients who received azathioprine belonged to 
the infliximab group (28 of 32 patients). Table 4 shows inf-
liximab with azathioprine for rescue therapy was superior to 
cyclosporine only for preventing colectomy (HR of infliximab 
with azathioprine compared to cyclosporine only, 0.073; 95% 
CI, 0.008 to 0.629).
Table 5 summarizes the results for the secondary end-points 
studied. Length of hospital stay after rescue therapy was shorter 
in the infliximab group (p<0.001). The rates of corticosteroid 
dependence after 12 months did not differ between the two 
groups (p=0.190). The rates of adverse events also did not differ 
between the two groups (p=0.359). Pancytopenia was observed 
in one patient from each group. No serious operation-related 
complication occurred in both groups. 
DISCUSSION 
Corticosteroids are the mainstay of therapy for severe ulcer-
ative colitis.21-23 However, at least one third of patients fail to 
respond to this treatment and ultimately undergo colectomy.22,24 
In this population, rescue therapy with cyclosporine or inflix-
imab has been used in recent years in an effort to decrease the 
rates of colectomy.18 However, there are theoretical and practical 
arguments regarding the use of infliximab versus cyclosporine.12 
In one retrospective study in Korea, corticosteroids and cyclo-
sporine combination therapy had no additional benefit over 
prolonged corticosteroids therapy alone.25
This study showed that colectomy-free survival was not af-
fected by selection of drugs, infliximab versus cyclosporine, as 
a rescue therapy in patients with severe corticosteroid-refractory 
UC. This result was similar to the European hospital study. A 
randomized controlled trial which compared cyclosporine with 
infliximab in intravenous corticosteroid-resistant UC as a sal-
vage therapy was previously performed at 27 European hospi-
tals between June 1, 2007, and August 31, 2010.17 One hundred 
fifteen patients with acute severe steroid-refractory UC were re-
cruited to receive either 2 mg/kg daily intravenous cyclosporine 
followed by an oral formulation (4 mg/kg daily) for 3 months, 
or infliximab (5 mg/kg) at weeks 0, 2, and 6. Clinical responses 
at day 7 and steroid-free remission at day 98 were comparable 
between the groups (about 60%), with no differences in terms of 
colectomy rates or adverse events.17 An early response (7 days) 
to either therapy exceeded 80%.17
In our study, when intravenous cyclosporine was successful 
at inducing remission, it was switched to oral azathioprine as 
described in other studies.26 In the literature, oral cyclosporine 
was reported to fail in maintaining remission for longer periods. 
As an alternative to oral cyclosporine, tacrolimus has also been 
successfully used in previous studies.27,28
In our study, however, infliximab seemed to be more effective 
than cyclosporine in terms with colectomy rate in the univari-
ate analysis. At 12 months, the rate of colectomy was 30% and 
3% in the cyclosporine and the infliximab groups, respectively 
(p=0.034). The difference between the results of univariate and 
multivariate analysis may be the higher frequency of the use of 
azathioprine in the infliximab group than in the cyclosporine 
Table 3. Cox Proportional Hazard Model for Colectomy
Parameter HR (95% CI) p-value
Disease extent
   Nonextensive
   Extensive
Azathioprine
Drug for rescue therapy
   Cyclosporine
   Infliximab
1
6.9×104 (<0.001–4.116×10122)
0.329 (0.044–2.482)
1
0.166 (0.013–2.088)
0.936
0.281
0.164
HR, hazard ratio; CI, confidence interval.
Table 4. Cox Proportional Hazard Model for Colectomy in Patients 
Treated with Either Cyclosporine Alone or Infliximab with Azathio-
prine
Parameter HR (95% CI) p-value
Disease extent
   Nonextensive
   Extensive
Drug for rescue therapy
   Cyclosporine only
   Infliximab with azathioprine
1
6.4×104 (<0.001–1.517×10172)
1
0.073 (0.008–0.629)
0.955
0.017
HR, hazard ratio; CI, confidence interval.
Table 5. Secondary End-Points
Parameter Cyclosporine (n=10) Infliximab (n=33) p-value
Length of hospital stay after rescue therapy, day
Patients on steroids at 12 months
Serious adverse events 
41.8 (0–94)
0 
1 (10.0)
6.6 (0–38)
5 (15.2)
1 (3.0)
<0.001
0.190
0.359
Data are presented as median (range) or number (%).
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group. In the subgroup analysis of our study, infliximab with 
azathioprine was superior to cyclosporine only for preventing 
colectomy. 
Our data, which was colectomy rate of 60% in the cyclospo-
rine group, are in agreement with the observational data report-
ed by Leuven, which showed that 88% of patients with initial 
cyclosporine-induced remission underwent colectomy by the 
end of the follow-up period (7 years).29 However, in infliximab-
treated patients, our results differed from those reported by the 
Swedish trial at 3 and 36 months,30,31 where the colectomy rates 
in the infliximab group were 29% and 50%, respectively. These 
differences can be partially explained by the dose of infliximab. 
There was a report that showed data on colectomy rates at 12 
months from the ACT I and II trials, which involved a multiple 
infusion regimen.32 These trials reported a lower colectomy rate 
of 10% for infliximab versus 17% for placebo.32 An analysis 
of the time to response in these two trials revealed that 63% of 
the total 74% who fully responded to the three infusions did so 
after the first dose, which increased to 86% of the total respond-
ers by the second dose.32 In our study, the patients in the inflix-
imab group received infusions every 8 weeks. It is well known 
that the number of infliximab infusions affects outcomes, with 
higher early colectomy rates in those receiving a single infusion 
compared with those receiving two or more infusions.12,13,33,34
In a Korean multicenter retrospective study, infliximab was 
effective and safe in the treatment of active UC. The rates of 
clinical responses and remission were 87% and 45% at week 8. 
That study was the first to show the efficacy of infliximab in 
Asian UC patients, and the results were superior to the previous 
Western studies. The study, however, showed the efficacy of 
infliximab without group comparison. Our study has the merit 
that the first study on comparison of efficacy of rescue thera-
pies in Korean patients with severe corticosteroid-refractory 
UC. In addition, it showed that the efficacy for preventing col-
ectomy did not differ between the two drugs, infliximab versus 
cyclosporine. We think, however, this result do not imply that 
cyclosporine is as useful as infliximab. Although incidence of 
severe adverse events did not differ between both groups in the 
study, generally cyclosporine has more risks of adverse events 
compared to infliximab.2,35 According to our subgroup analysis 
in patients treated with either cyclosporine only or infliximab 
with azathioprine, infliximab with azathioprine was more ef-
fective for preventing colectomy than cyclosporine without 
azathioprine. Therefore, infliximab with azathioprine could be 
preferentially considered rather than cyclosporine alone in the 
clinical setting of severe steroid refractory UC. 
The limitations of this study include the retrospective nature 
of the study design and the comparisons that were made be-
tween the two groups enrolled during different periods of time. 
This type of limitation should be overcome by well-designed 
prospective studies. Moreover, the small sample size limits the 
results as there were large ranges in baseline patient character-
istics, making it difficult to precisely compare the two popula-
tions. However, the data obtained from this study are quite 
reliable considering the fact that the characteristics of the two 
groups were comparable using our internal database system for 
medical records. The main outcome in this study was colectomy 
rate, which was not biased by subjective evaluation. Addition-
ally, the clinical management of severe colitis has not changed 
within the last two decades. 
In conclusion, there was no difference between infliximab 
and cyclosporine with respect to prevent colectomy in severe 
corticosteroid-refractory UC patients. Infliximab with azathio-
prine, however, may be more effective than cyclosporine only 
for preventing colectomy.
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